Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Galectin‑1 binds GRP78 to promote the proliferation and metastasis of gastric cancer.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: D.A. Spandidos Country of Publication: Greece NLM ID: 9306042 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1791-2423 (Electronic) Linking ISSN: 10196439 NLM ISO Abbreviation: Int J Oncol Subsets: MEDLINE
- Publication Information:
Publication: <2003->: Athens, Greece : D.A. Spandidos
Original Publication: Athens, Greece : Lychnia,
- Subject Terms:
- Abstract:
The present study aimed to investigate the potential molecular mechanisms by which galectin‑1 (Gal‑1) and glucose‑regulated protein 78 (GRP78) influence the development of malignant gastric cancer (GC). Immunohistochemistry and western blotting were used to map the expression and location of the Gal‑1 gene in the 80 paraffin‑embedded GC samples, 16 fresh samples and surrounding tissues. Gal‑1 was overexpressed and knocked down using lentiviral vectors in the human GC cell lines HGC‑27 and AGS. Through the use of the Cell Counting Kit‑8 assay, clone formation assay, wound healing assay, invasion assay and tumor xenograft, the possible biological roles of Gal‑1 were further evaluated. The downstream interacting proteins were predicted by the BioGRID database, and GRP78 was chosen for further investigation. Immunofluorescence labeling and Co‑IP were used to confirm the connection. The statistical tests utilized were the two‑tailed paired Student's t‑test, χ 2 test, Kaplan‑Meier and Cox regression analysis, and Spearman's rank correlation coefficients. In GC, Gal‑1 is extensively expressed and has the potential to interact with GRP78. Poor prognosis is linked to high levels of GRP78 and Gal‑1 expression in patients with GC. According to the functional study, Gal‑1 knockdown prevented cells from thriving and pushed Gal‑1 expression, which aided in the proliferation, migration and invasion of GC. Gal‑1 overexpression additionally aided the development of subcutaneous xenograft tumors. The mechanistic investigation proved that GRP78 and Gal‑1 interacted, accelerating the course of GC. Gal‑1 silencing had an inhibitory effect on the proliferation of HGC‑27 cells that was removed by ectopic GRP78 expression, whereas the stimulating effects of Gal‑1 overexpression in AGS cells were inhibited by GRP78 knockdown. In conclusion, Gal‑1 interacts with GRP78 to facilitate the advancement of GC. The Gal‑1/GRP78 axis is supported by the functional data of the present study as a possible GC treatment target.
- References:
Cell Biosci. 2020 Oct 01;10:115. (PMID: 33014334)
Glycobiology. 2006 Nov;16(11):137R-157R. (PMID: 16840800)
Exp Cell Res. 2018 Apr 1;365(1):1-11. (PMID: 29458176)
J Transl Med. 2019 Jul 3;17(1):216. (PMID: 31269957)
J Clin Invest. 2019 Dec 2;129(12):5553-5567. (PMID: 31710313)
Cell Death Dis. 2017 Oct 26;8(10):e3144. (PMID: 29072683)
J Biochem. 2003 Dec;134(6):869-74. (PMID: 14769876)
Cell Death Differ. 2006 Mar;13(3):363-73. (PMID: 16397583)
Protein Sci. 2021 Jan;30(1):187-200. (PMID: 33070389)
Cell Death Dis. 2018 Mar 16;9(4):416. (PMID: 29549328)
Mol Med Rep. 2017 Dec;16(6):8329-8334. (PMID: 28983626)
Ann Surg Oncol. 2006 Jul;13(7):999-1009. (PMID: 16788763)
Gene. 2017 Jul 15;620:15-22. (PMID: 28363780)
Cell Death Dis. 2019 Jun 26;10(7):504. (PMID: 31243264)
Int J Mol Sci. 2017 Jun 08;18(6):. (PMID: 28594391)
Lung Cancer. 2014 Apr;84(1):73-8. (PMID: 24560493)
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102. (PMID: 28407145)
Oral Oncol. 2008 Apr;44(4):325-34. (PMID: 17588803)
Immunol Lett. 2010 Jan 4;127(2):108-18. (PMID: 19874850)
J Surg Res. 2013 Nov;185(1):264-72. (PMID: 23759331)
Nat Rev Mol Cell Biol. 2012 Jan 18;13(2):89-102. (PMID: 22251901)
Mol Cell Biochem. 2015 Jan;398(1-2):55-62. (PMID: 25218495)
Cell Mol Life Sci. 2007 Jul;64(13):1679-700. (PMID: 17497244)
Life Sci. 2019 Jun 1;226:156-163. (PMID: 30978349)
Oncogene. 2013 Feb 14;32(7):805-18. (PMID: 22508478)
J Neuropathol Exp Neurol. 2002 Jul;61(7):585-96. (PMID: 12125737)
Cancer Manag Res. 2020 Mar 03;12:1569-1578. (PMID: 32184660)
JAMA Netw Open. 2021 Jul 1;4(7):e2118457. (PMID: 34309666)
Cell Death Dis. 2016 Apr 21;7:e2201. (PMID: 27100895)
J Am Soc Nephrol. 2014 Jul;25(7):1486-95. (PMID: 24511119)
Anim Cells Syst (Seoul). 2020 Sep 10;24(5):267-274. (PMID: 33209200)
Int J Mol Sci. 2020 Jun 04;21(11):. (PMID: 32512697)
Animal Model Exp Med. 2020 Apr 14;3(1):103-113. (PMID: 32318667)
Sci Rep. 2020 Jun 15;10(1):9666. (PMID: 32541810)
Tumour Biol. 2015 Mar;36(3):1859-69. (PMID: 25431258)
Curr Pharm Des. 2022;28(1):36-45. (PMID: 34579628)
Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
Aging (Albany NY). 2020 Nov 10;12(21):21837-21853. (PMID: 33170154)
Eur J Cancer. 2012 Aug;48(12):1914-21. (PMID: 22386573)
Cancer Biomark. 2017 Sep 7;20(3):273-281. (PMID: 28854502)
Cell Commun Signal. 2019 Jun 17;17(1):65. (PMID: 31208421)
CA Cancer J Clin. 2021 May;71(3):264-279. (PMID: 33592120)
Cancer Res. 2017 Apr 15;77(8):1968-1982. (PMID: 28202509)
Neoplasia. 2004 Jan-Feb;6(1):1-6. (PMID: 15068665)
Cancer Res. 2016 Oct 1;76(19):5657-5670. (PMID: 27698188)
J Exp Clin Cancer Res. 2019 Oct 22;38(1):423. (PMID: 31640796)
Scars Burn Heal. 2021 Jan 22;7:2059513120986687. (PMID: 33796337)
Glycobiology. 2019 Jul 1;29(7):599. (PMID: 31028384)
Cell Signal. 2017 Jul;35:154-162. (PMID: 28389416)
Onco Targets Ther. 2018 May 29;11:3237-3244. (PMID: 29881296)
- Contributed Indexing:
Keywords: galectin‑1; gastric cancer; glucose‑regulated protein 78; prognosis; progression
- Accession Number:
0 (Benzamides)
0 (Endoplasmic Reticulum Chaperone BiP)
0 (Galectin 1)
0 (HSPA5 protein, human)
0 (LGALS1 protein, human)
42HK56048U (Tyrosine)
59921-69-6 (1-nitrohydroxyphenyl-N-benzoylalanine)
- Publication Date:
Date Created: 20220930 Date Completed: 20221003 Latest Revision: 20221012
- Publication Date:
20221213
- Accession Number:
PMC9529432
- Accession Number:
10.3892/ijo.2022.5431
- Accession Number:
36177897
No Comments.